# Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

> **NCT07011550** · PHASE2 · SUSPENDED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Microsatellite-stable Colorectal Cancer
- Standard of Care
- Nivolumab
- Bevacizumab

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Bevacizumab
- **DRUG:** BMS-986340
- **DRUG:** Trifluridine + Tipiracil

## Key facts

- **NCT ID:** NCT07011550
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-08-15
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** PI Request
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011550, "Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07011550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*